Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue
暂无分享,去创建一个
Holger Lange | D. Eberhard | S. Schmechel | Steven J Potts | G David Young | G. D. Young | David A Eberhard | Joseph S. Krueger | Joseph S Krueger | Nicholas D Landis | Steven C Schmechel | S. Potts | H. Lange | Nicholas D. Landis
[1] K. Polyak,et al. Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.
[2] E. H. Simpson. Measurement of Diversity , 1949, Nature.
[3] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.
[4] T. D’alfonso,et al. Accurately Assessing HER-2/neu Status in Needle Core Biopsies of Breast Cancer Patients in the Era of Neoadjuvant Therapy: Emerging Questions and Considerations Addressed , 2010, The American journal of surgical pathology.
[5] Ross Ihaka,et al. Gentleman R: R: A language for data analysis and graphics , 1996 .
[6] S. Weinhouse. Discussion of Doctor Greenstein's paper. , 1956, Cancer research.
[7] D. Rimm,et al. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. , 2005, Journal of the National Cancer Institute.
[8] K. Schaefer,et al. Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases , 2010, Clinical Cancer Research.
[9] L. Huo. HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial , 2007 .
[10] D. Knowles,et al. Intratumoral Heterogeneity of HER-2/neu in Invasive Mammary Carcinomas Using Fluorescence In-Situ Hybridization and Tissue Microarray , 2006, International journal of surgical pathology.
[11] K. Polyak,et al. Breast tumor heterogeneity: causes and consequences , 2009, Breast Cancer Research.
[12] Marc K Halushka,et al. Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. , 2010, Human pathology.
[13] K. Allison,et al. Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity. , 2011, American journal of clinical pathology.
[14] H. Grabsch,et al. HER2 Expression in Gastric Cancer: Rare, Heterogeneous and of No Prognostic Value – Conclusions from 924 Cases of Two Independent Series , 2010, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[15] Dihua Yu,et al. Molecular predictors of response to trastuzumab and lapatinib in breast cancer , 2010, Nature Reviews Clinical Oncology.
[16] N. Jhala,et al. Using a higher cutoff for the percentage of HER2+ cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis. , 2008, American journal of clinical pathology.
[17] Calyampudi R. Rao. Diversity and dissimilarity coefficients: A unified approach☆ , 1982 .
[18] U. Lehmann,et al. Marked Intratumoral Heterogeneity of c-myc and CyclinD1 But Not of c-erbB2 Amplification in Breast Cancer , 2002, Laboratory Investigation.
[19] E. Davila,et al. The Clinical Importance of the Heterogeneity of HER2 neu , 2010, Case Reports in Oncology.
[20] D. Visscher,et al. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. , 2005, American journal of clinical pathology.
[21] Sang Joon Kim,et al. A Mathematical Theory of Communication , 2006 .
[22] A. Ruifrok,et al. Quantification of histochemical staining by color deconvolution. , 2001, Analytical and quantitative cytology and histology.
[23] Alastair I. Bartlett,et al. Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. , 2011, American journal of clinical pathology.
[24] Sandrine Pavoine,et al. The apportionment of quadratic entropy: a useful alternative for partitioning diversity in ecological data , 2005, Environmental and Ecological Statistics.
[25] Hua Guo,et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. , 2010, The American journal of pathology.
[26] W. Jochum,et al. HER2 genetic heterogeneity in breast carcinoma , 2011, Journal of Clinical Pathology.
[27] S. Fushida,et al. Gastric cancer heterogeneity , 1989, Cancer.
[28] M. Gönen,et al. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. , 2010, The Journal of clinical investigation.
[29] Raymond R Tubbs,et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. , 2009, Archives of pathology & laboratory medicine.
[30] Charles Theillet,et al. What do we learn from HER2-positive breast cancer genomic profiles? , 2010, Breast Cancer Research.